Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Study of SGN-40 (anti-huCD40 mAb), Lenalidomide (Revlimid, cc 5013), and Dexamethasone in Patients with Multiple Myeloma (MM).

Trial Profile

A Phase I Study of SGN-40 (anti-huCD40 mAb), Lenalidomide (Revlimid, cc 5013), and Dexamethasone in Patients with Multiple Myeloma (MM).

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 28 Oct 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dacetuzumab (Primary) ; Dexamethasone; Lenalidomide
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Sponsors Seagen; Seattle Genetics
  • Most Recent Events

    • 28 Jun 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 28 Jun 2010 Actual end date (May 2010) added as reported by ClinicalTrials.gov.
    • 08 Dec 2009 Results have been presented at the 51st Annual Meeting of the American Society of Hematology (ASH 2009), according to a Seattle Genetics media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top